Skip to main content
    A

    Ascendis Pharma AS (ASND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $271.19
    -0.54 (-0.20%)

    Market Cap: $18.06B

    Last updated: Nov 17, 2026 at 4:23 PM ET

    Ascendis Pharma AS (ASND) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ascendis Pharma AS (ASND) has a market cap of $18.06B. Revenue grew 86.87% over the last 12 months from the 12 months before. Its share count is up 12.66% from a year earlier.

    Total Valuation

    Market Cap$18.06B
    Latest price (Nov 17, 2026)$271.19

    Key Dates

    The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 9, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.57% in the quarter ended Sep 30, 2026 and grew 8.31% a year over 2 years.

    Shares Outstanding68.71M
    Shares Change (YoY)+12.66%
    Shares Change (QoQ)+0.57%
    Share Count Growth (2Y CAGR)+8.31%

    Valuation Ratios

    Sales and book value multiples are 13.4x and 11.0x. Its year-end P/S ranged from 15.8x to 811.8x from 2016 to 2025.

    P/S Ratio13.4x
    P/B Ratio11.0x
    P/TBV Ratio11.0x
    P/FCF Ratio31.5x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 60.7x EBITDA and 30.6x free cash flow.

    EV / EBITDA60.7x
    EV / FCF30.6x

    Price Statistics

    The stock is up 32.68% over 52 weeks and trades 11.73% above its 50-day average.

    Beta (1Y)0.44
    52-Week Change+32.68%
    1-Month Change+17.93%
    3-Month Change+4.46%
    6-Month Change+13.96%
    5-Year Change+65.73%
    10-Year Change+1190.55%
    Total Return (1Y)+32.68%
    Total Return (3Y CAGR)+41.85%
    Total Return (5Y CAGR)+12.79%
    Return vs SPY (1Y)+13.34%
    Max Drawdown (1Y)-19.66%
    Max Drawdown (3Y)-29.15%
    Sharpe Ratio (1Y)0.59
    Correlation with SPY (1Y)0.16
    50-Day Average$242.71
    200-Day Average$240.32
    52-Week Range$188.08 to $282.15
    RSI (14 Days)69.0
    Average Volume (20 Days)691.39K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.89x current liabilities, and total debt is 0.30x shareholder equity.

    Current Ratio2.89x
    Quick Ratio2.29x
    Debt / Equity0.30x
    Debt / EBITDA1.71x
    Interest Coverage1.52x

    Returns and Efficiency

    Return on invested capital is 12.51% over the last 12 months, against a 5-year average of -34.08%.

    Return on Equity (ROE)60.22%
    Return on Assets (ROA)37.23%
    Return on Invested Capital (ROIC)12.51%
    ROA (5Y Average)-39.21%
    ROIC (5Y Average)-34.08%
    Asset Turnover0.67x
    Inventory Turnover0.36x
    Receivables Turnover5.23x
    Cash Conversion Cycle751 days

    Scores

    ASND has an Altman Z-Score of 10.94, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score10.94
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was EUR 1.21B over the last 12 months.

    RevenueEUR 1.21B
    Revenue Growth (YoY)+86.87%
    Gross ProfitEUR 1.09B
    Operating IncomeEUR 222.29M
    Pretax IncomeEUR 271.18M
    Net IncomeEUR 890.37M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 61.73% of the EUR 2.43B in total assets.

    Working CapitalEUR 1.04B
    Shareholder EquityEUR 1.50B
    Tangible Book ValueEUR 1.50B
    Total AssetsEUR 2.43B
    Total LiabilitiesEUR 926.73M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After EUR 17.00M of capital spending, operating cash flow left EUR 516.87M of free cash flow.

    Operating Cash FlowEUR 533.87M
    Capital ExpendituresEUR 17.00M
    Free Cash FlowEUR 516.87M
    Depreciation and AmortizationEUR 18.33M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 18.40%.

    Gross Margin90.61%
    Operating Margin18.40%
    Pretax Margin22.44%
    Net Margin73.69%
    FCF Margin42.78%
    Gross Margin (5Y Average)77.45%

    Growth

    Revenue grew 138.21% a year over 3 years.

    Revenue Growth (3Y CAGR)+138.21%
    Revenue Growth (5Y CAGR)+150.93%

    Revenue and profit by year

    Peer Position

    Against 10 similar companies, ASND has the 6th highest P/S.

    P/S Ratio13.4x vs 12.1x median
    ROIC12.51% vs 3.48% median
    Revenue Growth (Trailing 4 Quarters, YoY)+86.87% vs +49.59% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ASND

    What is ASND's market cap?

    Ascendis Pharma AS has a market cap of $18.06B.

    How many shares of ASND are outstanding?

    Ascendis Pharma AS has 68.71M shares outstanding. The count is up 12.66% from a year earlier.

    Does ASND pay a dividend?

    No. Ascendis Pharma AS does not pay a dividend.